ak119
mAbexperimental
Clinical trial activity
7 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2020 (NCT04516564)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- 5'-nucleotidaseINHIBITOR
NT5E inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05846867 | Phase 1/Phase 2 (Phase 2) | May 10, 2023 | Akeso Pharmaceuticals, Inc., Harbin Medical University |
| NCT05689853 | Phase 1/Phase 2 (Phase 2) | Apr 14, 2023 | Akeso Pharmaceuticals, Inc., Chinese Academy of Medical Sciences |
| NCT05636267 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2022 | Akeso Pharmaceuticals, Inc., Shantou University |
| NCT05559541 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2022 | Akeso Pharmaceuticals, Inc., Tianjin Medical University |
| NCT05173792 | Phase 1 | Dec 22, 2021 | Akeso Pharmaceuticals, Inc., Fudan University, Tianjin Medical University |
| NCT04572152 | Phase 1 | Nov 30, 2020 | Akeso Pharmaceuticals, Inc. |
| NCT04516564 | Phase 1 | Sep 30, 2020 | Akeso Pharmaceuticals, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akeso Pharmaceuticals, Inc. | For profit | 7 | 7 | 2 | 2020 |
| Tianjin Medical University | Academic/Hospital | 2 | 0 | 2 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Harbin Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Shantou University | Academic/Hospital | 1 | 0 | 1 | 2022 |
6 organizations
Page 1 / 1